Oyster Therapeutics secured $60 million to expand a brain-focused pipeline aimed at overcoming size limitations in small-molecule degraders. The company’s lead program targets pathological tau for Alzheimer’s disease, with Eli Lilly participating in the financing. The fundraise signals growing investor willingness to back CNS-targeting modalities that aim to improve brain penetration while preserving degradation activity. Oyster’s approach is positioned as a platform attempt to address a recurring constraint in therapeutic design for the CNS. The Lilly participation underscores continued interest from major pharma in tau-directed mechanisms beyond monoclonal antibody approaches, especially when payload delivery and brain exposure are core engineering goals.
Get the Daily Brief